| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.073 | 0.03 |
| mRNA | JW-7-52-1 | GDSC1000 | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | BMS-708163 | GDSC1000 | pan-cancer | AAC | -0.071 | 0.03 |
| mRNA | Rapamycin | gCSI | pan-cancer | AAC | -0.11 | 0.03 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | -0.075 | 0.03 |
| mRNA | AC220 | GDSC1000 | pan-cancer | AAC | 0.073 | 0.03 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.074 | 0.04 |
| mRNA | AS601245 | GDSC1000 | pan-cancer | AAC | -0.073 | 0.04 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | -0.067 | 0.04 |
| mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | -0.069 | 0.04 |